Enanta Pharmaceuticals (NASDAQ:ENTA) Earns “Market Outperform” Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report released on Wednesday, Benzinga reports. JMP Securities currently has a $22.00 price target on the biotechnology company’s stock.

A number of other research analysts also recently weighed in on ENTA. Evercore ISI raised Enanta Pharmaceuticals to a strong-buy rating in a report on Tuesday, August 6th. HC Wainwright reissued a buy rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an underweight rating on the stock in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $20.00.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $11.04 on Wednesday. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $17.80. The stock has a market capitalization of $233.94 million, a PE ratio of -2.03 and a beta of 0.58. The business’s fifty day moving average is $11.98 and its 200 day moving average is $13.24.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The company had revenue of $17.97 million for the quarter, compared to the consensus estimate of $17.44 million. During the same quarter in the prior year, the company earned ($1.27) earnings per share. Enanta Pharmaceuticals’s revenue was down 4.9% on a year-over-year basis. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -5.3 EPS for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the transaction, the insider now owns 21,717 shares of the company’s stock, valued at $370,926.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 13.64% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares during the period. American Century Companies Inc. raised its stake in Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 7,287 shares during the period. Rhumbline Advisers raised its stake in Enanta Pharmaceuticals by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 1,548 shares during the period. Bank of New York Mellon Corp raised its stake in Enanta Pharmaceuticals by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 8,645 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at approximately $35,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.